Sei Investments Co. Acquires 39,455 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sei Investments Co. boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 196,808 shares of the company’s stock after acquiring an additional 39,455 shares during the quarter. Sei Investments Co.’s holdings in IDEXX Laboratories were worth $95,885,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IDXX. Atomi Financial Group Inc. increased its holdings in shares of IDEXX Laboratories by 3.4% in the 1st quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock valued at $344,000 after acquiring an additional 21 shares during the period. Ballentine Partners LLC lifted its stake in shares of IDEXX Laboratories by 1.9% during the 1st quarter. Ballentine Partners LLC now owns 1,188 shares of the company’s stock worth $641,000 after purchasing an additional 22 shares during the last quarter. Eads & Heald Wealth Management boosted its position in IDEXX Laboratories by 0.8% during the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock valued at $1,309,000 after purchasing an additional 22 shares in the last quarter. LRI Investments LLC boosted its position in IDEXX Laboratories by 21.7% during the second quarter. LRI Investments LLC now owns 129 shares of the company’s stock valued at $63,000 after purchasing an additional 23 shares in the last quarter. Finally, Mather Group LLC. grew its stake in IDEXX Laboratories by 4.2% in the second quarter. Mather Group LLC. now owns 594 shares of the company’s stock valued at $321,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on IDXX. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BTIG Research started coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Trading Down 2.0 %

NASDAQ:IDXX opened at $506.74 on Friday. The company has a market capitalization of $41.85 billion, a P/E ratio of 49.06, a PEG ratio of 4.17 and a beta of 1.33. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The firm has a fifty day simple moving average of $483.85 and a 200-day simple moving average of $499.16.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The business’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.67 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.